Europese Unie - Nederlands - EMA (European Medicines Agency)

shionogi b.v. - ospemifene - postmenopauze - geslachtshormonen en modulatoren van het genitale systeem, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

animedica-herstellungs - butorfanoltartraat 5.83 mg/ml - eq. butorfanol 4 mg/ml - oplossing voor injectie - 4 mg/ml - butorfanoltartraat 5.83 mg/ml - butorphanol - hond; kat

Europese Unie - Nederlands - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochloride - multiple sclerose, relapsing-remitting - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 en 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - vildagliptine - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 en 5. 1 voor de beschikbare gegevens over verschillende combinaties).

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformine hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - enalaprilmaleaat 20 mg; hydrochloorthiazide 12,5 mg - tablet - 20 mg - 12,5 mg - enalaprilmaleaat 20 mg; hydrochloorthiazide 12.5 mg - enalapril and diuretics